Maclean R - Search Results

1

The direct and indirect cost burden of Crohn's disease and ulcerative colitis.

Gibson TB, Ng E, Ozminkowski RJ, Wang S, Burton WN, Goetzel RZ, Maclean R. Gibson TB, et al. Among authors: maclean r. J Occup Environ Med. 2008 Nov;50(11):1261-72. doi: 10.1097/JOM.0b013e318181b8ca. J Occup Environ Med. 2008. PMID: 19001952

2

The impact of rheumatoid arthritis on medical expenditures, absenteeism, and short-term disability benefits.

Ozminkowski RJ, Burton WN, Goetzel RZ, Maclean R, Wang S. Ozminkowski RJ, et al. Among authors: maclean r. J Occup Environ Med. 2006 Feb;48(2):135-48. doi: 10.1097/01.jom.0000194161.12923.52. J Occup Environ Med. 2006. PMID: 16474262

3

The direct and indirect cost burden of acute coronary syndrome.

Johnston SS, Curkendall S, Makenbaeva D, Mozaffari E, Goetzel R, Burton W, Maclean R. Johnston SS, et al. Among authors: maclean r. J Occup Environ Med. 2011 Jan;53(1):2-7. doi: 10.1097/JOM.0b013e31820290f4. J Occup Environ Med. 2011. PMID: 21187788

4

Systematic review of studies of productivity loss due to rheumatoid arthritis.

Burton W, Morrison A, Maclean R, Ruderman E. Burton W, et al. Among authors: maclean r. Occup Med (Lond). 2006 Jan;56(1):18-27. doi: 10.1093/occmed/kqi171. Epub 2005 Nov 11. Occup Med (Lond). 2006. PMID: 16286432 Review.

5

Productivity cost model of the treatment of rheumatoid arthritis with abatacept.

Burton WN, Morrison A, Yuan Y, Li T, Marioni RE, Maclean R. Burton WN, et al. Among authors: maclean r. J Med Econ. 2008;11(1):3-21. doi: 10.3111/13696990701748837. J Med Econ. 2008. PMID: 19450107

6

Responsiveness of patient reported outcomes including fatigue, sleep quality, activity limitation, and quality of life following treatment with abatacept for rheumatoid arthritis.

Wells G, Li T, Maxwell L, Maclean R, Tugwell P. Wells G, et al. Among authors: maclean r. Ann Rheum Dis. 2008 Feb;67(2):260-5. doi: 10.1136/ard.2007.069690. Epub 2007 Sep 10. Ann Rheum Dis. 2008. PMID: 17846044 Clinical Trial.

7

Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to tumor necrosis factor-alpha antagonists.

Vera-Llonch M, Massarotti E, Wolfe F, Shadick N, Westhovens R, Sofrygin O, Maclean R, Li T, Oster G. Vera-Llonch M, et al. Among authors: maclean r. J Rheumatol. 2008 Sep;35(9):1745-53. Epub 2008 Jul 15. J Rheumatol. 2008. PMID: 18634164

8

Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment.

Russell AS, Wallenstein GV, Li T, Martin MC, Maclean R, Blaisdell B, Gajria K, Cole JC, Becker JC, Emery P. Russell AS, et al. Among authors: maclean r. Ann Rheum Dis. 2007 Feb;66(2):189-94. doi: 10.1136/ard.2006.057018. Epub 2006 Sep 19. Ann Rheum Dis. 2007. PMID: 16984942 Free PMC article. Clinical Trial.

9

Item response theory methods can improve the measurement of physical function by combining the modified health assessment questionnaire and the SF-36 physical function scale.

Martin M, Kosinski M, Bjorner JB, Ware JE Jr, Maclean R, Li T. Martin M, et al. Among authors: maclean r. Qual Life Res. 2007 May;16(4):647-60. doi: 10.1007/s11136-007-9193-5. Epub 2007 Mar 3. Qual Life Res. 2007. PMID: 17334829 Clinical Trial.

10

Cost-effectiveness modeling of abatacept versus other biologic agents in DMARDS and anti-TNF inadequate responders for the management of moderate to severe rheumatoid arthritis.

Russell A, Beresniak A, Bessette L, Haraoui B, Rahman P, Thorne C, Maclean R, Dupont D. Russell A, et al. Among authors: maclean r. Clin Rheumatol. 2009 Apr;28(4):403-12. doi: 10.1007/s10067-008-1060-4. Epub 2008 Dec 17. Clin Rheumatol. 2009. PMID: 19089488

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

339 results

Search Page